Sanofi, GSK to supply US govt with 100 million doses of Covid-19 vaccine

The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established

The post Sanofi, GSK to supply US govt with 100 million doses of Covid-19 vaccine appeared first on Pharmaceutical Business review.

Novartis gets EC nod for Cosentyx drug in paediatric psoriasis

Psoriasis, a life-long systemic inflammatory disease, is said to significantly affect the patients’ quality of life, both physically and emotionally. Cosentyx is claimed to be the first and

The post Novartis gets EC nod for Cosentyx drug in paediatric psoriasis appeared first on Pharmaceutical Business review.

FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma

The supplemental Biologics License Application (sBLA) for Tecentriq was granted under priority review.  The review was also conducted under Project Orbis, an initiative of the FDA Oncology Center

The post FDA approves Roche’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma appeared first on Pharmaceutical Business review.

Pfizer says Covid-19 vaccine may be needed regularly

Evidence has not emerged yet on how long coronavirus antibodies could protect against the disease, noted Bloomberg. Also, data from early trials have not demonstrated that a vaccine

The post Pfizer says Covid-19 vaccine may be needed regularly appeared first on Pharmaceutical Business review.

TAGRISSO granted FDA breakthrough therapy status in EGFR-mutated lung cancer

The Food and Drug Administration’s (FDA) BTD is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition

The post TAGRISSO granted FDA breakthrough therapy status in EGFR-mutated lung cancer appeared first on Pharmaceutical Business review.

SAB Biotherapeutics announces first participant dosed in phase 1 clinical trial of SAB-176 for seasonal influenza

SAB-176 is a novel anti-influenza human immunoglobulin G (IgG) immunotherapy designed to address the limitations of current treatment for severe seasonal influenza. This fully human polyclonal antibody therapeutic

The post SAB Biotherapeutics announces first participant dosed in phase 1 clinical trial of SAB-176 for seasonal influenza appeared first on Pharmaceutical Business review.

Takeda gets FDA breakthrough therapy status for pevonedistat to treat higher-risk HR-MDS

MDS is a rare form of bone marrow-related cancer, which will be resulted due to irregular blood cell production within the bone marrow. Pevonedistat, a first-in-class NEDD8-activating enzyme

The post Takeda gets FDA breakthrough therapy status for pevonedistat to treat higher-risk HR-MDS appeared first on Pharmaceutical Business review.

FDA grants breakthrough therapy designation to Merck’s MK-6482 in VHL disease-associated RCC

The FDA also granted orphan drug designation to MK-6482 for VHL disease. These designations are based on data from a Phase 2 trial evaluating MK-6482 in patients with

The post FDA grants breakthrough therapy designation to Merck’s MK-6482 in VHL disease-associated RCC appeared first on Pharmaceutical Business review.

Roche’s tocilizumab fails to achieve primary endpoints for Covid-19-related pneumonia

The phase III COVACTA study of tocilizumab did not reach its primary endpoint of improved clinical status in hospitalised adult patients with severe Covid-19 associated pneumonia. Roche’s trial

The post Roche’s tocilizumab fails to achieve primary endpoints for Covid-19-related pneumonia appeared first on Pharmaceutical Business review.

Nura Bio launches to discover and develop neuroprotective drug

Alpna Seth, PhD, a leader in the global biotechnology industry, is President and Chief Executive Officer of Nura Bio. The Column Group led the company’s $73 million Series

The post Nura Bio launches to discover and develop neuroprotective drug appeared first on Pharmaceutical Business review.